WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 8, 211-234. Review Article ISSN 2277–7105

UNVEILING THE FUTURE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY

Dhakane Sumeet[1], Jain Rahul[2] and Joshi Neeta[1]*

[1]R & D Neon Laboratories Limited, MIDC Society, Palghar, Maharashtra, India.

[2]Director, Neon Laboratories Limited, MIDC Society, Palghar, Maharashtra, India.

Article Received on
22 February 2025,

Revised on 14 March 2025,
Accepted on 04 April 2025

DOI: 10.20959/wjpr20258-36194

***Corresponding Author**
Dr. Joshi Neeta
R & D Neon Laboratories Limited, MIDC Society, Palghar, Maharashtra, India.

ABSTRACT

In the ever-evolving landscape of pharmaceutical research, a groundbreaking shift is occurring with the combination of Artificial Intelligence (AI) in field of drug discovery. Traditional methods, laden with trial and error, resource-intensive experiments, and time constraints, are giving way to a data-driven revolution. AI, with its computational prowess, navigates the complexities of genomics, proteomics, and biological systems, transforming drug discovery into a strategic, predictive process. From target identification and validation using machine learning and network analysis to AI-driven drug design and optimization through generative models and reinforcement learning, the innovations are profound. Virtual screening, predictive analytics, and personalized medicine, empowered by AI, redefine efficiency, accuracy, and cost-effectiveness in drug development. Furthermore, AI's role in drug repurposing, automation of lab processes, natural language processing, drug safety prediction, and clinical trial optimization herald a new era where technology accelerates the pace of discovery, ensuring safer and more effective medications for the future.

KEYWORDS: Artificial Intelligence, Network Analysis, Generative Models, Reinforcement Learning, Virtual Screening, Predictive Analytics, Personalized Medicine, Drug Repurposing, Lab Automation with AI, Target Identification.

INTRODUCTION

In the dynamic field of pharmaceutical research, traditional methods of drug discovery are undergoing a significant transformation. The intricate process, guided by biology, chemistry,

and clinical translation, has traditionally relied on extensive trial and error, resource-intensive experiments, and substantial time investments.[1,2] However, the emergence of AI marks a revolutionary shift beyond conventional boundaries.

Traditional drug discovery has been a complex journey, navigating through numerous potential drug candidates without guaranteed success. It involves meticulous target identification, followed by time-consuming synthesis and testing, leading to prolonged timelines and high costs.[3] Here comes AI, a technological marvel set to reshape drug discovery. The key distinction lies not just in efficiency but in a fundamental shift from intuition-driven processes to precise, data-driven methodologies.[4,5]

In traditional drug discovery, researchers heavily depend on expertise and intuition for target identification and molecule design, conducting experiments in a stepwise manner with significant time and resource investments.[3] In contrast, AI brings computational power to analyze vast datasets, decipher complex biological relationships, and foresee with unparalleled accuracy.[6]

The core difference is in AI's ability to learn and evolve. While traditional methods may struggle with the complexity of biological systems, AI excels. It navigates genomics, proteomics, and other -omics intricacies, revealing patterns and insights beyond human capability. It represents a paradigm shift from labor-intensive "search and test" to a more strategic "predict and refine" approach.[7]

As we explore the contrast between traditional and AI-driven drug discovery, we uncover the layers of innovation AI introduces. From target identification to predictive modeling and personalized medicine, the universe is experiencing a transformative shift.[4] Various AI based approaches are shown in Fig 1.



Fig. 1: Artificial Intelligence (AI) in drug discovery.

Key insights on artificial intelligence

Artificial Intelligence (AI) is a division of computing science that endows machines with ability to emulate human intelligence. It operates through sophisticated algorithms and computational models, enabling machines to learn from data, recognize patterns, and make informed decisions. AI encompasses various subfields, including machine learning and neural networks, which enable systems to autonomously enhance their performance over time. Through repeated processes of data analysis, AI systems discern complex relationships, leading to the development of predictive models and intelligent decision-making capabilities. In essence, AI transforms raw data into actionable insights, offering unparalleled potential for advancements across scientific domains.

1) Target Identification and Validation

1.1 Target identification

Target identification include two major stages Data Analysis and Network Analysis as follows.

1.1.1 Data analysis

AI excels in processing large-scale biological data. Machine learning algorithms can analyze genomics, proteomics, and other omics data to identify potential targets associated with diseases. For example, algorithms can identify genes or proteins that are overexpressed or mutated in disease conditions.[8,9]

1.1.2 Network analysis

AI tools employ network biology to understand the complicated interactions within biological systems. They can identify key nodes in these networks, which may serve as potential drug targets.[10] Network-based approaches provide a holistic view of biological pathways and their dysregulation in diseases.[11]

1.2 Target validation

1.2.1 Predicting biological relevance

AI models can speculate biological relevance of identified targets. This involves assessing whether a target is implicated in the pathophysiology of a disease.[4] Various machine learning models, consisting deep learning, can integrate diverse biological data to make these predictions.[12]

1.2.2 Drug-Target interaction prediction

AI algorithms can predict how potential drugs interact with specific targets. This is crucial for understanding the potential efficacy and safety of a drug. Tools like Deep Chem and Cheminformatics platforms leverage AI to predict drug-target interactions.[8,13]



Fig. 2: Target validation by AI.

Certain AI tools for Target Identification and Validation are IBM Watson, DeepMind Alpha Fold and Open Targets which are present in the market.

IBM Watson for Drug Discovery is a tool that combines AI and data analytics to accelerate drug discovery. It can analyze diverse datasets to find out potential drug targets and identify their biological relevance. However this service is discontinued now.[8,14]

Deep Mind Alpha Fold, It was initially focused on protein folding, AlphaFold's capabilities extend to predicting protein interactions.[15] This can aid in understanding the role of specific proteins in diseases and validate them as potential drug targets. Whereas Open Targets is a pre-competitive consortium that uses AI to integrate and analyze genetic, genomic and chemical data to find out and validate drug targets.[16]

2) Drug Design and Optimization

Artificial Intelligence algorithms can generate and optimize molecular structures for potential drug candidates. This accelerates the process of drug design, making it more efficient and cost-effective.



Fig. 3: Artificial Intelligence in drug Design & Optimization.

AI algorithms in drug design leverage generative models, predictive models, reinforcement learning, and optimization strategies to explore and optimize the vast chemical space efficiently. This scientific approach enhances the speed and cost-effectiveness of drug discovery (Fig 3.), contributing to the accelerated development of novel therapeutic agents.[8]

2.1 Generative models for molecular structures

2.1.1 Variational Autoencoders (VAEs)

VAEs are genre of generative model that can learn the latent space of molecular structures. By capturing the underlying distribution of chemical features, VAEs can generate novel molecular structures that adhere to the learned chemical rules.[17] E.g. Tableau, Power BI.

2.1.2 Generative Adversarial Networks (GANs)

GANs includes a generator and a discriminator, working in tandem. The generator is responsible for generation of molecular structures, and discriminator evaluates their authenticity. GANs learn to generate realistic and diverse molecular structures via adversarial training.[18]

2.2 Predictive models for bioactivity

2.2.1 Quantitative Structure Activity Relationship (QSAR)

AI-driven QSAR models examine the correlation in the chemical structure of a molecule and its biological activity along with computational toxicology assessment. These models predict how changes in the molecular structure will affect the bioactivity, aiding in the optimization

of drug candidates.[19] Some of available tool for this are QSARINS, DERK, SARAH and QSAR TOOLBOX.

2.2.2 Deep learning for bioactivity prediction

Deep neural networks, including graph neural networks, process molecular graphs to predict bioactivity. These models can discern intricate patterns in the molecular structure that contribute to the desired biological effects.

2.3 Reinforcement learning in drug design

Reinforcement Learning (RL) is utilized to improve molecular structures based on specific objectives, such as maximizing bioactivity or minimizing side effects. RL agents learn to iteratively modify molecular structures to achieve the desired properties through trial and error.[20]

2.4 De novo drug design

2.4.1 Evolutionary algorithms

Evolutionary algorithms, inspired by natural selection, can generate and iteratively improve molecular structures. These algorithms explore chemical space and select structures with optimal properties, mimicking the principles of evolution.[21]

2.4.2 Monte Carlo Tree Search (MCTS)

MCTS algorithms navigate vast combinatorial space of molecular structures.[22] By intelligently sampling and exploring the chemical space, MCTS identifies promising candidates for further optimization.[23]

2.5 Cost Reduction and Efficiency

2.5.1 High-Throughput virtual screening

AI-driven virtual screening methods rapidly evaluate extensive chemical libraries, recognize potential drug candidates. This notably reduces time and cost associated with experimental screening.Eg.AutoDock/AutoDock-VINA.[24]

2.5.2 In Silico ADMET Prediction

AI models anticipate Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of drug candidates.[25] This enables the elimination of unsuitable candidates initially in the design process, streamlining the development pipeline[26] E.g. ADMETlab 2.0.

2.6 Transfer Learning and Knowledge Integration

2.6.1 Transfer learning

AI models mentored on large datasets can transfer knowledge to specific drug design tasks. Pre-trained models, for example, can capture general molecular features and adapt to specific optimization objectives.[27]

2.6.2 Knowledge graphs

Integration of knowledge graphs enhances drug design by incorporating information on biological pathways, target interactions, and known drug structures. AI algorithms leverage this contextual information for more informed design decisions.[28,29]

3) Virtual screening

Virtual screening is a pivotal computational strategy in drug discovery, leveraging artificial intelligence (AI) models to identify the binding affinity of potential drug candidates to specific biological targets. This predictive approach enables researchers to strategically prioritize molecules for further experimental testing, ultimately minimizing the number of compounds that need to be synthesized and tested in the laboratory.[30]

The process begins with the compilation of extensive chemical databases containing millions of molecular structures. Researchers then identify a biological target, typically a protein associated with a disease, such as a receptor or enzyme.[31] AI models, often based on machine learning algorithms, are trained using known interactions between molecules and the chosen target. During training, these models learn intricate patterns and features contributing to binding affinity.[32,33]

The predictive power of virtual screening lies in the scoring function employed by the trained AI model. This function evaluates various molecular characteristics, including shape, electrostatics, and hydrogen bonding, to estimate how well a specific compound is likely to bind to the selected target. The compounds are subsequently ranked based on their predicted binding affinity scores, with higher-ranked molecules considered more likely to establish strong interactions with the target.[34]

Once the virtual screening process is complete, the top-ranked compounds undergo experimental validation in the laboratory. This step involves assays and experiments to confirm the predicted binding affinities and assess the biological activity of the compounds.

Virtual screening, fueled by AI, significantly expedites the drug discovery process by reducing the list of potential drug candidates.[35]

The advantages of virtual screening with AI are manifold. It enhances efficiency by streamlining the initial stages of drug discovery, leading to considerable time savings. Additionally, the reduction in the number of compounds requiring synthesis and experimental testing contributes to substantial cost savings in drug development. Researchers benefit from a more focused approach, concentrating their experimental efforts on a smaller, more promising subset of compounds.[4]

However, challenges exist, including the dependence on high-quality and diverse training data for accurate predictions. Virtual screening simplifies the understanding of complex biological systems, and predictions may not fully capture the intricacies of in vivo interactions. Ethical considerations, particularly regarding the accountable use of AI in drug discovery and potential biases in training data, must be taken into consideration.[8]

Virtual screening, empowered by AI models, is a valuable computational tool that significantly impacts drug discovery. It quickens the identification and prioritization of potential drug candidates as well as contributes to a more efficacious and cost-efficient drug development process.

4) Predictive analytics

Predictive analytics, bolstered by AI, is a powerful methodology in drug discovery that involves the analysis of extensive datasets to ascertain patterns and forecast the potential success of a drug candidate. This analytical approach enables informed decision-making regarding which compounds are more likely to advance through clinical trials successfully.[4]

In the realm of drug development, predictive analytics begins with the compilation of diverse datasets containing information on molecular structures, biological activities, and other relevant parameters. AI algorithms, ranging from machine learning models to deep neural networks, are then employed to sift through this wealth of data and identify meaningful patterns.[36]

The predictive power of AI in this context lies in its potential to uncover intricate relationships between various factors, such as chemical features of drug candidates and their

efficacy or safety profiles. These models learn from historical data, discerning hidden patterns that may not be apparent through conventional analytical methods.[37]

As drug candidates progress through the various stages of development, predictive analytics plays an important role in forecasting their likelihood of success. It aids in predicting factors such as bioactivity, pharmacokinetics, and potential adverse effects. By doing so, researchers and pharmaceutical companies can prioritize and invest resources in compounds that show the greatest promise, increasing the probability of successful clinical trials.

This approach is particularly valuable in addressing challenges associated with the high attrition rates in drug development. Predictive analytics allows for the identification of potential issues early in the development process, guiding researchers in making decisions that enhance the chances of successful outcomes in later stages.[36,37]

In essence, predictive analytics with AI in drug discovery facilitates a more strategic and data-driven approach. It empowers researchers to make informed decisions at each stage of drug development, optimizing the allocation of resources and increasing the efficiency of the overall process. As a result, the integration of predictive analytics contributes to the acceleration of drug discovery and development of more effective and safe therapeutic interventions.

5) Personalized medicine

Personalized medicine, facilitated by the analytical power of AI, is a transformative pathway in healthcare that adapts medical treatment as per traits of each patient. In the context of drug response, AI analyzes patient data to discern subpopulations that may exhibit enhanced responses or specific sensitivities to particular drugs. This targeted approach allows for the development of therapies that are personalized to the unique genetic, molecular, and clinical profile of individual patients.[38]

The process begins with the aggregation of diverse patient data, encompassing genetic information, clinical history, lifestyle and other relevant parameters. AI algorithms, including machine learning models and data mining techniques, are then applied to analyze this extensive dataset. The goal is to recognize patterns, correlations and associations that might not be readily apparent through conventional statistical methods.[39]

In the field of drug response prediction, AI models can determine how individual patients are likely to respond to specific treatments. This analysis may include factors such as genetic variations, biomarker expression levels, and clinical indicators. By discerning these patterns, AI enables the identification of patient subpopulations that may experience enhanced efficacy or reduced adverse effects with a particular drug.[40]

Benefits of Personalized Medicine with AI

- Targeted therapies: Personalized medicine allows for the development of targeted therapies that are tailored to the specific characteristics of individual patients.
- Optimized treatment selection: AI helps clinicians choose the most appropriate treatment for a patient based on their unique genetic and clinical profile, potentially improving treatment outcomes.
- Reduced adverse effects: By identifying patients who may be more sensitive to certain drugs, personalized medicine aims to minimize adverse effects and improve overall treatment tolerability.
- Improved drug efficacy: Understanding individual variations in drug response enables the selection of treatments that are more likely to be effective for particular patient, optimizing therapeutic outcomes.

Some of common AI tools for personalized medicine are NantHealth, Foundation Medicine and Tempus.[38] NantHealth integrates genomic and clinical data to provide personalized treatment options. Their platform uses AI to analyze complex datasets for precision medicine applications.[41] Foundation Medicine employs AI to analyze genomic data and identify genomic alterations in tumors. This information is used to guide personalized treatment strategies in oncology.[42]

Tempus uses AI to analyze clinical and molecular data to assist in personalized cancer care. It provides insights into treatment options based on individual patient profiles.[43]

6) Drug repurposing

Imagine you have a box of crayons, each designed for a specific color. Now, think of these crayons as drugs, each made for a specific purpose. AI in drug repurposing is like having a super-smart friend who says, "Hey, what if we use the blue crayon to draw the sky instead of just coloring jeans?" AI looks at all these crayons, or drugs, and wonders if some might be

good for more than what they were originally made for.[44] Simplified flow chart for process of drug repurposing is shown in Fig 4.



Fig. 4: Drug repurposing.

This smart friend, which is AI, starts by looking at tons of information about the drugs—how they're built, what they were made to treat, and how they interact with our bodies. It's like studying the crayons to understand their colors and properties. Then, AI goes a step further. It connects the dots, finding patterns and similarities that humans might not notice. It's like discovering that the blue crayon also works well for coloring the ocean because it's similar to the sky.

Now, here comes the exciting part. AI predicts which drugs might be useful for treating different diseases.[45] It's like saying, "Hmm, this green crayon was made for grass, but it might just work for leaves too!" This prediction is based on the patterns AI found in the data. And just like that, AI helps researchers save time and money.[46] Instead of starting from scratch to create new drugs, they explore the crayon box they already have. It's like finding new uses for tools you already own, making the process efficient and cost-effective.[47,48]

Biovista, Reaxys and PharmGPS are some of AI tools used in drug repurposing. Biovista employs AI to analyze scientific literature, aiding researchers in discovering new uses for existing drugs.[49] Reaxys Medicinal Chemistry uses AI to explore chemical data, helping

researchers identify connections between drugs and new applications.[50] PharmGPS applies AI to biological and chemical data, facilitating the identification of drug repurposing opportunities by analyzing interactions with different biological pathways.[51,52] These tools act as intelligent guides, leveraging AI to navigate diverse data landscapes and uncover innovative drug repurposing possibilities.

7) Automation of lab processes

The automation of laboratory processes has undergone a notable change with the integration of AI-powered robotics. This innovative approach involves the deployment of robots equipped with advanced sensors, actuators, and artificial intelligence algorithms to carry out various tasks within a laboratory setting.[53] These tasks can range from routine activities such as sample handling and mixing substances to more complex experiments and data analysis. The primary objective is to streamline experimental workflows, increase operational efficiency, and minimize the time required for conducting experiments.[54]

One of the key advantages of AI-powered robotics in the laboratory is the substantial boost in efficiency. By automating repetitive and time-consuming tasks, these robotic systems enable researchers to focus their time and expertise on more complex and analytical aspects of their work. The precision and consistency offered by robots contribute to the reduction of human errors, enhancing the reproducibility of experimental results.[55]

Fig. 5: Lab automation equipments.

Several AI tools and platforms have emerged to facilitate the automation of laboratory processes as follows some of them are shown in Fig 5.

- Andrew Alliance: Andrew Alliance provides a robotic platform that integrates with various lab instruments. This platform utilizes AI to enhance liquid handling processes, ensuring accuracy and reproducibility in experiments.[56]
- Tecan Fluent® Laboratory Automation Solution: Tecan's Fluent® platform combines robotic automation with intelligent liquid handling. It is designed to streamline various lab processes, from sample preparation to analysis.[57]
- Labguru by Benchling: Labguru offers a comprehensive lab management platform with integrated AI capabilities. It assists in experiment planning, implimaentation, and data analysis, contributing to overall laboratory efficiency.[58]
- OT-2 by Opentrons: Opentrons' OT-2 is a compact robotic platform designed for laboratory automation. It can be programmed to perform a variety of tasks, providing versatility for different experiments.[59]
- LabWare LIMS: LabWare offers a Laboratory Information Management System (LIMS) with automation capabilities. This platform utilizes AI to manage and optimize lab workflows, enhancing overall laboratory efficiency.[60]
- STARlet by Hamilton Robotics: STARlet is a robotic platform by Hamilton Robotics specifically designed for liquid handling and sample processing. It integrates AI for precise and efficient lab automation.[61]

The integration of AI-powered robotics in laboratory processes represents a significant advancement in scientific research. These tools not only contribute to the efficiency and accuracy of experiments but also allow researchers to explore new possibilities and accelerate the pace of discovery in various fields of study.

8) Natural language processing

Natural Language Processing (NLP) is a domain of AI that focuses on bridging the gap between computers and human language. In the field of scientific research, NLP plays a crucial role by enabling computers to extract valuable information from diverse textual sources such as scientific literature, patents, and clinical trial reports. The objective is to empower machines to understand, interpret, and derive meaningful insights from the complex language used in scientific documents.[62]

NLP in scientific research operates through sophisticated algorithms that are trained to process and analyze textual data. These algorithms perform tasks such as text parsing,

sentiment analysis, and named entity recognition. In the context of scientific literature, NLP can identify key concepts, relationships between entities, and trends within a given field.[63] This capability is particularly valuable for researchers seeking to stay updated with the latest developments and findings in their respective domains.

The benefits of employing NLP in scientific research are multifaceted. Firstly, it facilitates the extraction of pertinent information, including key findings, methodologies, and conclusions, from voluminous scientific texts. NLP algorithms also excel in data summarization, condensing large volumes of text into concise overviews.[62] Moreover, NLP enables trend analysis by identifying emerging patterns and themes within the language used in scientific literature. Its semantic search capabilities further enhance researchers' ability to find specific information based on the meaning of the text.[64]

Several AI tools harness the power of NLP to assist researchers in navigating and extracting insights from scientific literature. For instance, PubTator employs NLP to extract information from biomedical literature, aiding in the identification of gene and disease associations. MetaMap is designed for mapping biomedical text to concepts in the Unified Medical Language System (UMLS), facilitating the identification of medical concepts in scientific literature[65] SciBite provides NLP solutions for standardizing scientific information from diverse textual sources.[66]

While Textpresso caters to the biological sciences, annotating and indexing relevant concepts in scientific literature[67] IBM Watson Natural Language Understanding leverages NLP for sentiment analysis, entity recognition, and key concept extraction in scientific documents.[14]

In essence, NLP emerges as a powerful tool in scientific research, enhancing the efficiency of information extraction and allowing researchers to keep pace with the dynamic landscape of scientific knowledge. These AI tools represent a symbiosis of advanced algorithms and linguistic analysis, providing researchers with the means to glean valuable insights from the ever-expanding body of scientific literature.

9) Drug Safety and Side Effects Prediction

In the realm of drug development, ensuring safety of potential medications is paramount. AI is playing a crucial role in this domain by aiding in the prediction of drug safety and potential side effects. The process involves the utilization of advanced machine learning models that

analyze diverse datasets, including biological information, clinical trial results, and historical data on drug reactions.[49] By discerning patterns and correlations within this complex data, AI models can predict potential safety issues associated with drug candidates, offering a proactive approach to identifying and mitigating risks.[68]

These AI models leverage a variety of data sources to make predictions. For instance, they may consider the molecular structure of the drug, known interactions with biological targets, and data from previous clinical trials.[6] By training on large datasets, these models develop the ability to recognize subtle patterns indicative of potential side effects, even those that may not be immediately apparent through conventional methods.[8]

One notable advantage of employing AI in drug safety prediction is the ability to detect issues early in the development process. This early identification allows researchers and pharmaceutical companies to take preemptive measures, potentially modifying drug formulations or adjusting dosages to enhance safety profiles. Additionally, it contributes to the reduction of late-stage failures in clinical trials, saving both time and resources.[4]

Several AI tools and platforms are dedicated to drug safety and side effects prediction:

- Advera Health Analytics: Advera focuses on pharmacovigilance and uses AI to analyze real-world data, such as adverse event reports, to predict and monitor drug safety issues.[69]
- Symmetry by Owkin: Symmetry utilizes machine learning to analyze biological, clinical, and real-world data to predict drug safety and efficacy. It aims to enhance the understanding of the safety profiles of drug candidates.[70]
- Biovista: It employs AI to analyze diverse biomedical data, including literature and clinical data, to predict potential side effects and safety concerns associated with drugs.[49]

The utilization of AI in drug safety and side effects prediction symbolize a significant advancement in pharmaceutical research. By harnessing the power of machine learning, these tools contribute to a more proactive and informed approach to drug development, ultimately leading to safer and more effective medications.

10) Clinical trial optimization

Clinical Trial Optimization, powered by artificial intelligence (AI), is a transformative way in the area of medical research that aims to streamline and improve the entire process of

conducting clinical trials. This optimization encompasses various aspects, including patient recruitment, identification of suitable trial sites, and the real-time analysis of data generated during the trials.[71]

One of the significant challenges in clinical trials is recruiting the right participants within a reasonable timeframe. AI plays a vital role in optimizing patient recruitment by leveraging advanced algorithms to analyze diverse datasets. These datasets may consist of electronic health records, genomic information, and other relevant patient data.[72] AI models can identify potential participants who meet the specific criteria for a trial, thereby expediting the recruitment process and ensuring that the trial includes a diverse and representative cohort.

Identifying suitable trial sites is another crucial aspect of clinical trial optimization. AI analyzes a range of factors, such as the availability of eligible patients, geographic considerations, and historical trial performance, to recommend optimal sites for conducting the trial. This strategic site selection contributes to the efficiency of the trial and facilitates the enrollment of participants.[73]

During the course of clinical trials, AI continues to play a important role in real-time data analysis. Traditional methods of data analysis can be time-consuming, potentially delaying critical decisions. Also AI algorithms can process and analyze incoming data in real time, providing researchers with timely insights into the trial's progress. This real-time analysis enables swift adjustments, if necessary, and enhances the overall efficiency of the trial.[71]

Trials.ai takes a holistic approach, leveraging AI to optimize trial design, site selection, and patient recruitment. Its comprehensive application streamlines the entire clinical trial process, providing researchers with valuable insights for efficient trial execution.[74]

Clinithink contributes to the optimization of clinical trials by focusing on unstructured clinical data. Through AI analysis, it facilitates patient cohort identification, enhancing recruitment precision and efficiency in critical early stages of clinical research.[75]

These AI-powered platforms collectively represent a transformative force, enhancing the efficiency, speed, and success of clinical trials, ultimately advancing the development of new medical interventions and therapies.

SUMMARY

The incorporation of Artificial Intelligence in pharmaceutical research marks a transformative shift from traditional, intuition-driven drug discovery to a precise, data-driven approach. AI's capabilities in target identification, drug design, virtual screening, predictive analytics, personalized medicine, drug repurposing, lab automation, natural language processing, drug safety prediction, and clinical trial optimization offer unprecedented efficiency, cost-effectiveness, and accuracy. The technology's ability to analyze vast datasets, predict outcomes, and uncover intricate biological relationships accelerates the development of novel therapeutic agents. Key AI tools, such as IBM Watson, DeepMind AlphaFold, and Open Targets, exemplify the market's response to this paradigm shift.

CONCLUSION

AI emerges as a powerful ally in the pharmaceutical industry, revolutionizing every stage of drug discovery and development. Its impact on efficiency, precision, and cost reduction is profound, offering researchers and pharmaceutical companies a strategic edge. As AI continues to evolve, the promise of safer, more effective medications and the optimization of clinical trials bring the prospect of groundbreaking medical interventions closer to reality. Ethical considerations and challenges notwithstanding, the fusion of AI with pharmaceutical medicine presents a compelling narrative of progress and innovation.

Funding

Not Applicable.

Conflicts of interest

Authors have no conflict of interest.

Ethics approval

Not applicable.

Informed consent

Not Applicable.

REFERENCES

1. Pirintsos S, Panagiotopoulos A, Bariotakis M, Daskalakis V, Lionis C, Sourvinos G, et al. From Traditional Ethnopharmacology to Modern Natural Drug Discovery: A

Methodology Discussion and Specific Examples. Molecules [Internet], 2022 [2023, 30]; 27. Available from: /pmc/articles/PMC9268545/

2. Hardy K. Paleomedicine and the Evolutionary Context of Medicinal Plant Use. Revista Brasileira De Farmacognosia [Internet], 2021 [2023, 30]; 31: 1. Available from: /pmc/articles/PMC7546135/
3. Hughes JP, Rees SS, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol [Internet], 2011 [2023, 30]; 162: 1239. Available from: /pmc/articles/PMC3058157/
4. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today [Internet], 2021 [2023, 30]; 26: 80. Available from: /pmc/articles/PMC7577280/
5. Wirtz BW, Weyerer JC, Geyer C. Artificial Intelligence and the Public Sector—Applications and Challenges. International Journal of Public Administration [Internet], 2019 [2023, 30]; 42: 596–615. Available from: https://www.tandfonline.com/doi/abs/10.1080/01900692.2018.1498103
6. Xu Y, Liu X, Cao X, Huang C, Liu E, Qian S, et al. Artificial intelligence: A powerful paradigm for scientific research. The Innovation, 2021; 2: 100179.
7. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol [Internet], 2022 [2023, 30]; 39. Available from: /pmc/articles/PMC9198206/
8. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics [Internet], 2023 [2023, 30]; 15. Available from: /pmc/articles/PMC10385763/
9. Sarker IH. AI-Based Modeling: Techniques, Applications and Research Issues Towards Automation, Intelligent and Smart Systems. SN Comput Sci, 2022; 3.
10. Zhang B, Tian Y, Zhang Z. Network biology in medicine and beyond. Circ Cardiovasc Genet, 2014; 7: 536–47.
11. Muzio G, O'Bray L, Borgwardt K. Biological network analysis with deep learning. Brief Bioinform [Internet], 2021 [2023, 30]; 22: 1515–30. Available from: https://dx.doi.org/10.1093/bib/bbaa257
12. You Y, Lai X, Pan Y, Zheng H, Vera J, Liu S, et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduction and Targeted Therapy, 2022; 7: 1 [Internet], 2022 [2023, 30]; 7: 1–24. Available from: https://www.nature.com/articles/s41392-022-00994-0

13. Xu L, Ru X, Song R. Application of Machine Learning for Drug–Target Interaction Prediction. Front Genet, 2021; 12: 680117. 5737-B19 IBM Watson for Drug Discovery - IBM Documentation [Internet]. [cited 2023 Sep 30]. Available from: https://www.ibm.com/docs/en/announcements/watson-drug-discovery?region=CAN
14. Binder JL, Berendzen J, Stevens AO, He Y, Wang J, Dokholyan N V., et al. AlphaFold illuminates half of the dark human proteins. Curr Opin Struct Biol, 2022; 74.
15. Koscielny G, An P, Carvalho-Silva D, Cham JA, Fumis L, Gasparyan R, et al. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res [Internet], 2017 [2023, 30]; 45: D985. Available from: /pmc/articles/PMC5210543/
16. Vogt M. Exploring chemical space — Generative models and their evaluation. Artificial Intelligence in the Life Sciences, 2023; 3: 100064.
17. Zhang H, Lee M. Recent Advances in Generative Adversarial Networks for Gene Expression Data: A Comprehensive Review. Mathematics, 2023; 11: 3055. [Internet], 2023 [2023, 30]; 11: 3055. Available from: https://www.mdpi.com/2227-7390/11/14/3055/htm
18. Bastikar V, Bastikar A, Gupta P. Quantitative structure–activity relationship-based computational approaches. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection [Internet], 2022 [2023, 30]; 191. Available from: /pmc/articles/PMC9300454/
19. Monte Carlo Tree Search: Implementing Reinforcement Learning in Real-Time Game Player | by Masoud Masoumi Moghadam | Towards Data Science [Internet]. [2023; 30]. Available from: https://towardsdatascience.com/monte-carlo-tree-search-a-case-study-along-with-implementation-part-1-ebc7753a5a3b
20. Corne D, Lones MA. Evolutionary Algorithms. Handbook of Heuristics [Internet], 2018; [2023, 30]; 1–22. Available from: https://link.springer.com/referenceworkentry/10.1007/978-3-319-07153-4_27-1
21. Zook A, Harrison B, Riedl MO. Monte-Carlo Tree Search for Simulation-based Strategy Analysis, 2019 [2023, 30]; Available from: http://arxiv.org/abs/1908.01423
22. Świechowski M, Godlewski K, Sawicki B, Mańdziuk J. Monte Carlo Tree Search: a review of recent modifications and applications. Artif Intell Rev [Internet], 2023 [2023, 30]; 56: 2497–562. Available from: https://link.springer.com/article/10.1007/s10462-022-10228-y
23. Clyde A, Galanie S, Kneller DW, Ma H, Babuji Y, Blaiszik B, et al. High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent

Inhibitor. J Chem Inf Model [Internet], 2022 [2023, 30]; 62: 116–28. Available from: https://pubs.acs.org/doi/full/10.1021/acs.jcim.1c00851

24. Kar S, Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin Drug Discov, 2020; 15: 1473–87.
25. Kar S, Roy K, Leszczynski J. In Silico Tools and Software to Predict ADMET of New Drug Candidates. Methods Mol Biol [Internet], 2022 [2023; 30], 2425: 85–115. Available from: https://pubmed.ncbi.nlm.nih.gov/35188629/
26. Liu Z, Roberts RA, Lal-Nag M, Chen X, Huang R, Tong W. AI-based language models powering drug discovery and development. Drug Discov Today, 2021; 26: 2593–607.
27. MacLean F. Knowledge graphs and their applications in drug discovery. Expert Opin Drug Discov [Internet], 2021 [2023, 30], 16: 1057–69. Available from: https://www.tandfonline.com/doi/abs/10.1080/17460441.2021.1910673
28. Nicholson DN, Greene CS. Constructing knowledge graphs and their biomedical applications. Comput Struct Biotechnol J, 2020; 18: 1414–28.
29. Vijayan RSK, Kihlberg J, Cross JB, Poongavanam V. Enhancing preclinical drug discovery with artificial intelligence. Drug Discov Today, 2022; 27: 967–84.
30. Wermuth CG, Villoutreix B, Grisoni S, Olivier A, Rocher JP. Strategies in the Search for New Lead Compounds or Original Working Hypotheses. The Practice of Medicinal Chemistry: Fourth Edition. Elsevier Inc, 2015.
31. Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine Learning in Drug Discovery: A Review. Artif Intell Rev [Internet], 2022 [2023, 30]; 55: 1947. Available from: /pmc/articles/PMC8356896/
32. Kingma DP, Welling M. An introduction to variational autoencoders. Foundations and Trends in Machine Learning, 2019; 12: 307–92.
33. Wermuth CG, Villoutreix B, Grisoni S, Olivier A, Rocher JP. Strategies in the Search for New Lead Compounds or Original Working Hypotheses. The Practice of Medicinal Chemistry: Fourth Edition. Elsevier Inc, 2015.
34. Gimeno A, Ojeda-Montes MJ, Tomás-Hernández S, Cereto-Massagué A, Beltrán-Debón R, Mulero M, et al. The Light and Dark Sides of Virtual Screening: What Is There to Know? Int J Mol Sci [Internet], 2019 [2023, 30]; 20. Available from: /pmc/articles/PMC6470506/
35. Askr H, Elgeldawi E, Aboul Ella H, Elshaier YAMM, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev

[Internet], 2023 [2023, 1]; 56: 5975–6037. Available from: https://link.springer.com/article/10.1007/s10462-022-10306-1

36. Han R, Yoon H, Kim G, Lee H, Lee Y. Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. Pharmaceuticals, 2023; 16, 1259 [Internet], 2023 [2023, 1]; 16: 1259. Available from: https://www.mdpi.com/1424-8247/16/9/1259/htm
37. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci [Internet], 2021 [2023, 1]; 14: 86. Available from: /pmc/articles/PMC7877825/
38. Ahmed Z, Mohamed K, Zeeshan S, Dong XQ. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database (Oxford) [Internet], 2020 [2023, 1]; 2020. Available from: /pmc/articles/PMC7078068/
39. Precision Medicine, AI, and the Future of Personalized Health Care - PMC [Internet]. [2023; 1]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877825/
40. Helping Payers and Providers Drive Better Outcomes | NantHealth [Internet]. [2023, 1]. Available from: https://nanthealth.com/resources/articles/helping-payers-and-providers-navigate-the-perfect-storm-to-drive-better-outcomes/
41. dbGaP Study [Internet]. [2023, 1]. Available from: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001179.v1.p1
42. Tempus | AI-enabled precision medicine [Internet]. [2023, 1]. Available from: https://www.tempus.com/
43. Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health [Internet], 2020 [2023, 1]; 2: e667–76. Available from: https://pubmed.ncbi.nlm.nih.gov/32984792/
44. Mohanty S, Harun AI Rashid M, Mridul M, Mohanty C, Swayamsiddha S. Application of Artificial Intelligence in COVID-19 drug repurposing. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020; 14: 1027–31.
45. Ravi S, Jadhav S, Vaidya A, Ghooi R. Repurposing drugs during the COVID-19 pandemic and beyond. Pharm Pat Anal, 2021; 10: 9–12.
46. Cong Y, Endo T. Multi-Omics and Artificial Intelligence-Guided Drug Repositioning: Prospects, Challenges, and Lessons Learned from COVID-19. OMICS, 2022; 26: 361–71.

47. Yang F, Zhang Q, Ji X, Zhang Y, Li W, Peng S, et al. Machine Learning Applications in Drug Repurposing. Interdiscip Sci, 2022; 14: 15–21.
48. Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, et al. AI in drug discovery and its clinical relevance. Heliyon [Internet], 2023 [2023, 1]; 9. Available from: /pmc/articles/PMC10302550/
49. Improve content discoverability across the entire drug discovery workflow- Reaxys Medicinal Chemistry |Elsevier Solutions [Internet]. [2023, 1]. Available from: https://www.elsevier.com/en-xm/solutions/reaxys/who-we-serve/pharma-rd/reaxys-medicinal-chemistry
50. Masuda T, Mimori K. Artificial intelligence-assisted drug repurposing via "chemical-induced gene expression ranking." Patterns [Internet], 2022 [2023, 1]; 3: 100470. Available from: /pmc/articles/PMC9023885/
51. Masuda T, Tsuruda Y, Matsumoto Y, Uchida H, Nakayama KI, Mimori K. Drug repositioning in cancer: The current situation in Japan. Cancer Sci, 2020; 111: 1039–46.
52. Borboni A, Reddy KVV, Elamvazuthi I, AL-Quraishi MS, Natarajan E, Azhar Ali SS. The Expanding Role of Artificial Intelligence in Collaborative Robots for Industrial Applications: A Systematic Review of Recent Works. Machines, 2023; 11: 111 [Internet], 2023 [2023, 1]; 11: 111. Available from: https://www.mdpi.com/2075-1702/11/1/111/htm
53. Maadi M, Khorshidi HA, Aickelin U. A review on human–ai interaction in machine learning and insights for medical applications. Int J Environ Res Public Health, 2021; 18: 1–21.
54. 3. Improvements ahead: How humans and AI might evolve together in the next decade | Pew Research Center [Internet]. [2023, 1]. Available from: https://www.pewresearch.org/internet/2018/12/10/improvements-ahead-how-humans-and-ai-might-evolve-together-in-the-next-decade/
55. Andrew Alliance - Pipetting tools and software for the scientific lab [Internet]. [2023; 1]. Available from: https://www.andrewalliance.com/
56. Fluent®Automated Workstation - Tecan [Internet]. [2023; 1]. Available from: https://www.tecan.com/fluent-automated-workstation
57. Lab Management Software | Laboratory System | Labguru [Internet]. [2023; 1]. Available from: https://www.labguru.com/
58. Opentrons | Lab Automation | Lab Robots for Life Scientists [Internet]. [2023; 1]. Available from: https://opentrons.com/?&utm_source=google&utm_campaign=Branded&utm_term=open

tron%20ot%202&utm_medium=cpc&hsa_tgt=kwd-1656601315811&hsa_cam=881433800&hsa_acc=2303351826&hsa_kw=opentron%20ot%202&hsa_mt=p&hsa_src=g&hsa_grp=55045114298&hsa_ad=595767467013&hsa_ver=3&hsa_net=adwords&gclid=Cj0KCQjwjt-oBhDKARIsABVRB0xbDsh2zbea6jEiG_hhFyJYlVcEhxX1iMmo71s4k40H3GKx9al2ZngaAmTfEALw_wcB&gclsrc=aw.ds

59. Alternatives to LIMS [Internet]. [2023; 1]. Available from: https://www.idbs.com/go/do-you-need-lims-row/?utm_source=Google&utm_medium=PPC&utm_campaign=GAds_LIMS_Alternatives_ROW_NA____NA_PPC_NA_&cmp=7014J000000ePXfQAM&gad=1&gclid=Cj0KCQjwjt-oBhDKARIsABVRB0w7s7ZujnckksNM2qq3knXjSvUj26Hg9BNwsRybhNWuxyGyqpRUdooaAkLaEALw_wcB
60. Genomic STARlet | View the Hamilton Genomic STARlet [Internet]. [2023; 1]. Available from: https://www.hamiltoncompany.com/automated-liquid-handling/assay-ready-workstations/genomic-starlet
61. What is Natural Language Processing and How Does it work? [Internet]. [2023; 1]. Available from: https://www.datalinknetworks.net/dln_blog/what-is-natural-language-processing-and-how-does-it-work
62. What is Natural Language Processing? An Introduction to NLP [Internet]. [2023; 1]. Available from: https://www.techtarget.com/searchenterpriseai/definition/natural-language-processing-NLP
63. Khurana D, Koli A, Khatter K, Singh S. Natural language processing: state of the art, current trends and challenges. Multimed Tools Appl [Internet], 2023 [2023, 1]; 82: 3713–44. Available from: https://link.springer.com/article/10.1007/s11042-022-13428-4Meta Map.
64. Semantic Analytics & Clean Data Intelligence Experts | SciBite [Internet]. [2023; 1]. Available from: https://scibite.com/
65. Müller HM, Kenny EE, Sternberg PW. Textpresso: an ontology-based information retrieval and extraction system for biological literature. PLoS Biol [Internet], 2004 [2023; 1]: 2. Available from: https://pubmed.ncbi.nlm.nih.gov/15383839/
66. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The Role of AI in Drug Discovery: Challenges, Opportunities, and

Strategies. Pharmaceuticals [Internet], 2023 [2023; 1], 16: 891. Available from: /pmc/articles/PMC10302890/

67. Soldatos TG, Kim S, Schmidt S, Lesko LJ, Jackson DB. Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports. CPT Pharmacometrics Syst Pharmacol [Internet], 2022 [2023; 1], 11: 540. Available from: /pmc/articles/PMC9124355/
68. Sarkar C, Das B, Rawat VS, Wahlang JB, Nongpiur A, Tiewsoh I, et al. Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. Int J Mol Sci [Internet], 2023 [2023, 1]; 24: 2026. Available from: /pmc/articles/PMC9916967/
69. Askin S, Burkhalter D, Calado G, El Dakrouni S. Artificial Intelligence Applied to clinical trials: opportunities and challenges. Health Technol (Berl) [Internet], 2023 [2023, 1]; 13: 203. Available from: /pmc/articles/PMC9974218/
70. Harrer S, Shah P, Antony B, Hu J. Artificial Intelligence for Clinical Trial Design. Trends Pharmacol Sci, 2019; 40: 577–91.
71. Delso G, Cirillo D, Kaggie JD, Valencia A, Metser U, Veit-Haibach P. How to Design AI-Driven Clinical Trials in Nuclear Medicine. Semin Nucl Med, 2021; 51: 112–9.
72. Trials.ai – Our Smart Protocol technology helps teams design better clinical trials with AI [Internet]. [2023; 1]. Available from: https://www.trials.ai/
73. AI Solutions | Clinical Data Solutions | Life Science & Healthcare [Internet]. [2023; 1]. Available from: https://www.clinithink.com/